Emcitate
Emcitate ingredients
| Active ingredient | Strength |
|---|---|
| Tiratricol | 350 ug/1 |
What Emcitate is used for
The FDA lists the approved uses on the official label (below). In the EU, tiratricol is approved as Emcitate for:
Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Emcitate
- Generic name
- Tiratricol
- Made by
- Rare Thyroid Therapeutics International AB
- Forms
- Tablet, For Suspension
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA220963
- On the US market since
- 2026
Official information
- MedlinePlus drug information (search for Tiratricol)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Emcitate?
Emcitate (Tiratricol) is a specialist medicine made by Rare Thyroid Therapeutics International AB, approved by the US FDA.
What are the ingredients of Emcitate?
Emcitate contains Tiratricol (350 ug/1).
Is Emcitate approved in Europe?
The same active substance is approved in the EU as Emcitate.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA